U.S., Nov. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07918846) titled 'A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease' on Nov. 02.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), as a therapy to reduce the risk of major adverse cardiovascular events (MACE) in adults living with overweight or obesity and established cardiovascular disease (CVD), with or without type 2 diabetes mellitus (T2DM).
Study Start Date: Jan. 06, 2027
Study Type: INTERVENTIONAL
Condition:
Overweight
Obe...